| Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human A Basit, NK Neradugomma, C Wolford, PW Fan, B Murray, RH Takahashi, ... Molecular Pharmaceutics 17 (11), 4114-4124, 2020 | 64 | 2020 |
| Structure-based design of tricyclic NF-κB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K) GM Castanedo, N Blaquiere, M Beresini, B Bravo, H Brightbill, J Chen, ... Journal of medicinal chemistry 60 (2), 627-640, 2017 | 59 | 2017 |
| Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin OS Bains, RH Takahashi, TA Pfeifer, TA Grigliatti, RE Reid, KW Riggs Drug Metabolism and Disposition 36 (5), 904-910, 2008 | 51 | 2008 |
| Characterization of the Ontogeny of Hepatic UDP‐Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes J Badée, N Qiu, AC Collier, RH Takahashi, WF Forrest, N Parrott, ... The Journal of Clinical Pharmacology 59, S42-S55, 2019 | 47 | 2019 |
| Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C] cobimetinib, a MEK inhibitor, in humans RH Takahashi, EF Choo, S Ma, S Wong, J Halladay, Y Deng, I Rooney, ... Drug Metabolism and Disposition 44 (1), 28-39, 2016 | 46 | 2016 |
| Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine H Zhang, C Wolford, A Basit, AP Li, PW Fan, BP Murray, RH Takahashi, ... Drug Metabolism and Disposition 48 (7), 528-536, 2020 | 31 | 2020 |
| Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1, 2, 3, 5, 6, 7-Hexahydro-s-indacen-4-yl) carbamoyl)-6-(methylamino)-6, 7-dihydro-5 H-pyrazolo [5, 1-b][1, 3 … C McBride, L Trzoss, D Povero, M Lazic, G Ambrus-Aikelin, A Santini, ... Journal of Medicinal Chemistry 65 (21), 14721-14739, 2022 | 25 | 2022 |
| Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug–drug interactions JQ Ly, K Messick, A Qin, RH Takahashi, EF Choo Molecular pharmaceutics 14 (5), 1754-1759, 2017 | 22 | 2017 |
| Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor EF Choo, S Woolsey, K DeMent, J Ly, K Messick, A Qin, R Takahashi Drug Metabolism and Disposition 43 (6), 864-869, 2015 | 21 | 2015 |
| Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro RH Takahashi, OS Bains, TA Pfeifer, TA Grigliatti, RE Reid, KW Riggs Drug Metabolism and Disposition 36 (6), 991-994, 2008 | 21 | 2008 |
| The effect of allelic variation in aldo-keto reductase 1C2 on the in vitro metabolism of dihydrotestosterone RH Takahashi, TA Grigliatti, RE Reid, KW Riggs Journal of Pharmacology and Experimental Therapeutics 329 (3), 1032-1039, 2009 | 19 | 2009 |
| Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate AG Bart, RH Takahashi, X Wang, EE Scott Drug Metabolism and Disposition 48 (2), 86-92, 2020 | 17 | 2020 |
| Applying stable isotope labeled amino acids in micropatterned hepatocyte coculture to directly determine the degradation rate constant for CYP3A4 RH Takahashi, SK Shahidi-Latham, S Wong, JH Chang Drug Metabolism and Disposition 45 (6), 581-585, 2017 | 17 | 2017 |
| Absorption, distribution, metabolism, and excretion of [14C] GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway … Q Yue, YH Chen, T Mulder, A Deese, R Takahashi, PJ Rudewicz, ... Drug Metabolism and Disposition 39 (6), 952-965, 2011 | 17 | 2011 |
| Investigations into the mechanisms of pyridine ring cleavage in vismodegib SC Khojasteh, Q Yue, S Ma, G Castanedo, JZ Chen, J Lyssikatos, ... Drug Metabolism and Disposition 42 (3), 343-351, 2014 | 12 | 2014 |
| Mixed matrix method provides a reliable metabolite exposure comparison for assessment of Metabolites in Safety Testing (MIST) RH Takahashi, C Khojasteh, M Wright, CECA Hop, S Ma Drug metabolism letters 11 (1), 21-28, 2017 | 11 | 2017 |
| Elucidating the Mechanism of Cytochrome P450–Mediated Pyrimidine Ring Conversion to Pyrazole Metabolites with the BACE1 Inhibitor GNE-892 in Rats R Takahashi, S Ma, A Deese, Q Yue, H Kim-Kang, Y Yi, M Siu, KW Hunt, ... Drug Metabolism and Disposition 42 (5), 890-898, 2014 | 10 | 2014 |
| Novel mechanism of decyanation of GDC-0425 by cytochrome P450 RH Takahashi, JS Halladay, M Siu, Y Chen, CECA Hop, SC Khojasteh, ... Drug Metabolism and Disposition 45 (5), 430-440, 2017 | 9 | 2017 |
| Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with … RH Takahashi, WF Forrest, AD Smith, J Badee, NH Qiu, S Schmidt, ... Drug Metabolism and Disposition 49 (9), 760-769, 2021 | 8 | 2021 |
| Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of … RA Craig, BM Fox, C Hu, KW Lexa, M Osipov, AP Thottumkara, ... Journal of Medicinal Chemistry 65 (24), 16290-16312, 2022 | 7 | 2022 |
